Antagonistic antibodies targeting the G-protein C-X-C chemokine receptor 4 (CXCR4) hold promising therapeutic potential in various diseases. We report for the first time the detailed mechanism of action at a molecular level of a potent anti-CXCR4 antagonistic antibody (MEDI3185). We characterized the MEDI3185 paratope using alanine scanning on all 6 complementary-determining regions (CDRs). We also mapped its epitope using CXCR4 mutagenesis to assess the relative importance of the CXCR4 N-terminal peptide, extracellular loops (ECL) and ligand-binding pocket. We show that the interaction between MEDI3185 and CXCR4 is mediated mostly by CDR3H in MEDI3185 and ECL2 in CXCR4. The MEDI3185 epitope comprises the entire ECL2 sequence, lacks any so-called 'hot-spot' and is remarkably resistant to mutations. The structure of MEDI3185 variable domains was modeled, and suggested a b-strand/b-strand interaction between MEDI3185 CDR3H and CXCR4 ECL2, resulting in direct steric hindrance with CXCR4 ligand SDF-1. These findings may have important implications for designing antibody therapies against CXCR4.
Introduction
G-protein C-X-C chemokine receptor 4 (CXCR4) is a 7-transmembrane spanning protein that binds the chemokine stromal derived factor-1 (SDF-1). [1] [2] [3] This pathway regulates many physiological processes, such as leukocyte trafficking, stem cell mobilization, and embryonic development of the cardiovascular, haematopoietic , and central nervous systems. [4] [5] [6] [7] Furthermore, CXCR4 plays an important role in many human pathologies, including human immunodeficiency virus (HIV) infection, rheumatoid arthritis, and cancer metastasis and development. In particular, HIV-1 strains use CXCR4 as a co-receptor for viral entry into host cells. 8, 9 In rheumatoid arthritis, the CXCR4/SDF-1 pathway stimulates the migration of memory T cells and inhibits T cell apoptosis. 10 Moreover, CXCR4 is broadly expressed in various types of cancers. [11] [12] [13] [14] [15] [16] These observations suggest that CXCR4 is an important target to prosecute. To this effect, various inhibitors have been developed including small molecules, peptides and antibodies. [17] [18] [19] [20] [21] A small molecule antagonist, AMD3100, has shown therapeutic potential for HIV infection, inflammatory diseases, stem-cell mobilization and cancers. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Peptide-based inhibitors such as T22, 32 T140 33 and their derivatives 34, 35 have also shown promising activity in various disease models. 17 Much efforts have been devoted to characterize the mechanism of action of such inhibitors, including structure-activity relationship studies, computational molecular modeling, and structural characterization. [36] [37] [38] [39] [40] [41] Recently, crystal structures of CXCR4 bound to a small molecule antagonist (IT1t) and a cyclic peptide (CVX15) 40 were reported. Both inhibitors bind into a pocket formed by transmembrane helices I, II, III, and VII. While IT1t occupies only part of this pocket, CVX15 fills most of the volume and also interacts with residues of the second extracellular loop (ECL2). This pocket has been hypothesized to be the signaling trigger for SDF-1 and several acidic residues were identified as crucial for the interaction with SDF-1 or HIV-1. 42 Such studies have provided a molecular basis for the antagonistic activity of low-molecular weight CXCR4 inhibitors.
Alternate CXCR4 blocking strategies using mAbs have also been pursued. In particular, both mouse and rat mAbs directed against CXCR4 have shown activity in inhibiting HIV infection and cancer migration/growth in animal models. [43] [44] [45] [46] [47] More recently, a fully human mAb (BMS-936564) has demonstrated tumor growth inhibition activity and is currently in clinical trials to treat relapsed/refractory hematologic malignancies. 20 We have also reported a fully human antagonistic anti-CXCR4 mAb, MEDI3185 (IgG1, k/.
21 MEDI3185 can inhibit tumor growth in hematologic tumors as a single-agent and shows combination activity in ovarian tumor models. While interest in developing anti-CXCR4 mAb therapy increases, so does understanding the molecular basis for the corresponding mechanism(s) of action.
Several studies have probed the extracellular portion of CXCR4 using mutagenesis, and concluded that anti-CXCR4 mAbs can recognize different portions, such as the N-terminal peptide, ECL1, 2 or 3. 43, [48] [49] [50] However, the molecular mechanisms by which anti-CXCR4 antagonistic mAbs exert their inhibitory activity remain largely unknown.
In an effort to elucidate molecular mechanisms by which mAbs can inhibit CXCR4, we have determined the binding mode of MEDI3185. We characterized the paratope of MEDI3185 using alanine scanning on its 6 complementarity-determining regions (CDRs), mapped its epitope by CXCR4 mutagenesis and modeled the structure of its variable domains. We propose a novel mode of CXCR4 inhibition, different from that of small-molecule/peptide inhibitors.
Results

Determination of MEDI3185 paratope
Alanine scanning was performed across all 6 MEDI3185 CDRs to identify its paratope. The variable domain sequences of MEDI3185 are shown in Figure 1 , with CDRs defined as per Kabat. 51 Of note, CDR3H comprises 20 amino acids, a relatively long span when compared with the corresponding average length in human (namely 13.1 residues). 52 CDR1H, 2H, 1L, 2L and 3L all belong to known canonical classes based on their primary sequences (corresponding to PDB ID numbers 2fbj, 1igc, 1ikf, 1lmk and 1tet, respectively). Thus, we used their corresponding canonical structures [53] [54] [55] to select residues at or near the apex of each loop for mutagenesis (excluding positions known to be part of the V L /V H interface) 56 because these are more likely to be solvent exposed and antigen-accessible. For CDR3H, a large (15/20) portion of residues in its middle section was chosen for substitutions. Thirteen 51 are bold and underlined, whereas residues marked with asterisks indicate positions where mutations were introduced. Figure 2 . Binding characterization of MEDI3185 variants to CXCR4. Thirteen variants, single or combinatorial, were generated by replacing select CDR residues with Ala or Gly (for A 50 Figure 4 . (a) Amino acid alignment of human (hu) and mouse (mo) CXCR4. Secondary structural elements are shown according to the crystal structure of CXCR4. 40 Underlined sequences were swapped between human and mouse CXCR4 to construct chimeric variants. (b) Nomenclature and schematic representation of KO and KI CXCR4 variants based on the crystal structure of CXCR4. 40 The N-terminal peptide was added using Discovery Studio. Ten chimeric variants were constructed by swapping in or out various segments of human (green) into mouse (cyan) CXCR4 (KI), or of mouse into human CXCR4 (KO). (c) MEDI3185 binding to various CXCR4 chimeric variants by FACS. CXCR4 expression was monitored using mAb 2B11. The y axis represents side scatter characteristics, while the x axis represents the mean fluorescence intensity (MFI).
flow cytometry (Fig. 2) (Fig. 3A) . All mutants expressed well on the surface of CHO cells (Fig. 3B ) as monitored using mAb 2B11, which recognizes CXCR4 N-terminal peptide.
57 MEDI3185 binding to these CXCR4 variants was assessed by flow cytometry. All variants exhibited similar binding compared to wild-type CXCR4 (Fig. 3B) , suggesting that the ligand binding pocket, although constituting the binding site of small molecule and peptide-based CXCR4 inhibitors, 40, 58 is not involved in the interaction with MEDI3185. Indeed, the CXCR4 small molecule inhibitor AMD3100 did not affect binding of MEDI3185 to CXCR4 (Fig. 3C) . Thus, MEDI3185 interacts with CXCR4 with a distinct mode of action.
To probe CXCR4 N-terminal peptide and its 3 ECLs, a series of chimeric human/mouse variants were constructed. More precisely, we generated 8 loss-of-function (knock-out, 'KO') variants by replacing human segments with their mouse counterparts, and 2 gain-of-function (knock-in, 'KI') by grafting human regions into the mouse molecule (Figs. 4A-B). Murine CXCR4 was selected for generating the chimeric variants because it shares 90% sequence identity with human CXCR4 (Fig. 4A) , and is only faintly recognized by MEDI3185 (Figs. 4C-D). All chimeric variants expressed well on the surface of CHO cells as monitored with anti-CXCR4 mAb 2B11, which recognizes both human and mouse CXCR4 (Fig. 4C) . The N-terminal peptide, ECL1 and ECL3 did not appear to play a significant role (Figs. 4C-D; KO_Nterm, KO_ECL1, KO_ECL3 and KO_N-termCECL3). Only upon substituting human ECL2 with the (Figs. 4A-B) . Interestingly, MEDI3185 still bound well to both KO variants (Figs. 4C-D) . Likewise, when grafted onto the murine sequence, either portion of human ECL2 conferred good binding to MEDI3185 (Figs. 4C-D) . Thus, both ECL2 portions significantly contribute to the interaction with MEDI3185.
To further refine the MEDI3185 epitope, Ala scanning mutagenesis was applied to ECL2 (excluding C 186 ). All ECL2 residues were substituted with Ala (except A 175 and A 180 , which were substituted by Asp), alone or in combination, and assessed for MEDI3185 binding ( Table 1) . We also replaced either of the 2 above-mentioned ECL2 portions with unstructured glycineserine linkers (G 3 SG 3 S) in an effort to identify whether welldefined main-chain conformations play a significant role in interacting with MEDI3185. All variants expressed well on the surface of CHO cells as monitored using mAb 2B11 ( Table 1) . Strikingly, none of the Ala or Asp mutations had any significant effect on MEDI3185 binding. MEDI3185 binding was only abolished upon substituting either portion of ECL2 with G 3 S linkers. These results further confirm that MEDI3185 epitope is 'dispersed' throughout the entire ECL2. It also follows that: 1) ECL2 side-chains as a whole do not seem to significantly contribute to MEDI3185 binding; and 2) the main-chains of ECL2 residues likely play a major role in this interaction and their overall conformation is critical to MEDI3185 binding.
We then examined if MEDI3185 cross-reacts with human CXCR7, a closely related receptor for SDF-1. 59 We found that MEDI3185 does not bind to CXCR7-positive (and CXCR4-negative) MCF-7 human breast cancer cells (Fig. 5) . Thus, the MEDI3185 epitope appears to be specific to CXCR4.
Homology modeling of MEDI3185
To gain further insight on MEDI3185 interaction with CXCR4, the 3-dimensional structure of the variable domains of MEDI3185 was predicted by homology modeling using antibody structure modeling tools implemented in Discovery Studio. First, framework structures were modeled using the following high homology templates: 1DEE for V L (97% identity), 3EYQ for V H (95% identity) and 1DEE for V L /V H interface (92% identity). Second, CDR conformations were modeled using a set of loop templates, including 2JIX for CDR1L, 2L and 3L (90.9%, 100%, and 77.8% identity, respectively), 8FAB for CDR1H (80% identity), 3EYQ for CDR2H (94.1% identify) and 1ZA3 for CDR3H (30% identity), as summarized in Table 2 . Third, although structure prediction is fairly accurate for antibody frameworks and CDRs with well-defined canonical structures, modeling CDR3H has proven more challenging and been shown to yield average root mean square deviation values of 3.0 A from the corresponding X-ray crystal structures. 60 Therefore, we built this CDR using a template identified using socalled 'H3 rules'. 61, 62 These rules are thought to more accurately model CDR3H and rely on the overall analysis of primary sequence, nature and positions of select residues, as well as known structural motifs. We identified 4LKC as the CDR3H template which belongs, along with MEDI3185 CDR3H, to the K G sub-type. Both boast identical length and similar composition ( Table 2) . Using 4LKC as the new structural template, MEDI3185 CDR3H was predicted to form a b-turn structure with a kinked base protruding from a base formed by the other 5 CDRs (Fig. 6 ).
After refinement, the top-ranked model was inspected for clashes between atoms. In such regions, limited minimization was performed for side-chains using CHARMm 63,64 implemented in Discovery Studio. The final model was validated using Profiles 3D and Ramachandran plots (96% Ramachandran favored residues).
Mode of interaction between MEDI3185 and CXCR4
Guided by the epitope mapping results, we used the ZDOCK 65 and RDOCK 66 algorithms to create a model of the MEDI3185/CXCR4 complex. The modeled MEDI3185 Fv structure was docked to human CXCR4 (PDB ID number 3ODU) using ZDOCK. All predicted docked structures were clustered and filtered for poses involving the ECL2 epitope region in the binding interface. The resulting~50 poses in the top 2 clusters were manually examined to select poses containing the major MEDI3185 CDR3H paratope in the interface. The qualified 10 poses were further refined and evaluated using RDOCK. All top poses with low RDOCK energies (< -15 kcal.mol -1 ), including electrostatic and desolvation energies, were advanced for binding interface analysis. The final model was selected to be consistent with all the mutagenesis results.
Based on mutagenesis and modeling data, we propose a new mode of interaction for MEDI3185/CXCR4 based on a b-strand/b-strand interaction between CDR3H and ECL2 ( Figure 7) . On the epitope side, the entire ECL2 contributes to the interaction with MEDI3185, mostly through its main-chains as described above. This is in very good agreement with our proposed b-strand/b-strand-based mode of binding where main chain/main chain hydrogen bonds constitute the primary contacts. In addition, the conformational complementarity between MEDI3185 CDR3H and CXCR4 ECL2 hairpins may also substantially contribute to the interaction. However, a detailed analysis of the binding interface would require a crystal structure. On the paratope side and as shown in Figure 8 , CDR3H mutations which substantially reduced binding to CXCR4 are localized in ). Therefore, most of CDR3H b-hairpin structure is involved in interacting with CXCR4. These results also agree well with the proposed mode of binding to the extent that although CDR3H side-chain mutations may not break the b-strand/b-strand interaction, they could distort the conformation of the apex loop portion of CDR3H and affect binding to CXCR4. Based on our model, MEDI3185 antagonistic activity is mediated via sterically blocking access of SDF-1 to CXCR4. A "2-site" model has previously been hypothesized for the CXCR4/SDF-1 interaction, 40, [67] [68] [69] [70] [71] whereby CXCR4 N-terminal peptide serves as a docking domain ('site 1') for SDF-1, followed by interaction of SDF-1 with the pocket defined by CXCR4 transmembrane helices ('site 2'). A model of the CXCR4/SDF-1 complex has been proposed using a combination of computational, biochemical and biophysical approaches. 72 This model is consistent with the hypothesis of a 1:1 stoichiometry and a 2-site receptorligand interaction. Moreover, a recent crystal structure of the complex of CXCR4 bound to a viral chemokine has clearly demonstrated that CXCR4 interacts with the chemokine via its N-terminal peptide (site 1) and transmembrane pocket (site 2), 73 further confirming the 2-site receptor-ligand interaction mode. Although MEDI3185 does not bind either of these 2 sites, superimposing the model of the CXCR4/MEDI3185 complex to the structure of CXCR4 bound to the viral chemokine (PDB ID number 4RWS) or SDF-1 (model) shows that MEDI3185 blocks binding of CXCR4 to its ligands via steric hindrance ( Figures 9A-B) .
Discussion
In fine, an actual crystal structure of the MEDI3185/CXCR4 complex will be required to provide a detailed molecular understanding of this interaction. This is a challenging proposition given the GPCR nature of CXCR4. In the meantime, our study represents the first thorough molecular characterization of an interaction between an anti-CXCR4 antagonistic mAb and CXCR4. It also reveals important new findings related to the function and design of therapeutic antibodies against CXCR4.
MEDI3185 contains a long 20-aa CDR3H. Interestingly, one study has described the sequences of a panel of anti-CXCR4 mAbs identified from phage libraries, 50 and the most potent antagonist molecules exhibited a long (17 to 18 aa) CDR3H. Additionally, BMS-936564, a human anti-CXCR4 mAb currently in clinical trials also exhibits a long (16 aa) CDR3H (patent entitled "Treatment of hematologic malignancies with an anti-cxcr4 antibody; WO 2013071068A2). Thus, a long CDR3H may be an important attribute for antagonistic anti-CXCR4 antibodies.
Of note, ECL2 appears to be a shared epitope for many reported anti-CXCR4 neutralizing mAbs, and those recognizing other ECLs or the N-terminal peptide exhibit no or only weak activity in inhibiting the CXCR4/ SDF-1 signaling pathway and CXCR4-mediated HIV infection. 43, [48] [49] [50] 74 However, a unique feature of the MEDI3185 epitope is the lack of a hot-spot on ECL2. It is dispersed throughout the entire ECL2 and involves both the b-hairpin structure (A 175 -I 185 ) and the loop at its base (D 187 -V 196 ). Epitopes for previously described mouse antagonistic mAbs 12G5, 701, 708, 716, 717 and 718 all involve 2 hot-spot ECL2 residues at E 179 and D 181 . 43, 49 These 2 residues are located at the top of the ECL2 b-hairpin structure and are easily accessible by short CDR loops. Indeed, one of these mAbs (12G5) exhibits a short (9 aa) CDR3H. 75 In contrast, MED-I3185's long CDR3H allows it to reach the stem region of the ECL2 hairpin and the loop at its base. Furthermore, we also find here that MEDI3185 epitope is resilient to individual and combined Ala mutations. Such a robustness of MEDI3185 epitope may constitute an advantage to efficiently target a wide population of CXCR4 due to its known propensity to exhibit significant conformational heterogeneity. 76 Additional binding characterization using CXCR4 from different primary tissues would be required to further validate this hypothesis.
Cell-type dependent glycosylation of CXCR4 also contributes its heterogeneity. CXCR4 contains 2 potential N-glycosylation sites at positions of N 11 Y 12 T 13 (in the N-terminal peptide) and N 176 V 177 S 178 (in ECL2). Mutations of the N 11 glycation site was shown to decrease the binding of the N-terminal peptide-recognizing mAb 2B11. 77 However, binding of ECL2-recognizing mAb 12G5 was not affected by mutations of either N 11 or N 176 . 77, 78 Similarly to 12G5, we expect little to no impact of these different N-glycosylation profiles on MEDI3185 binding because MEDI3185 only binds to ECL2 and mutating N 176 VSE 179 to a stretch of Ala did not affect the binding of MEDI3185 ( Table 1) . Here again, additional binding experiments using cells isolated from primary tissues would be needed to confirm.
Some GPCR drugs act as inverse agonists rather than neutral antagonists 79 and exhibit potential therapeutic benefits when compared with neutral antagonists in diseases where increased levels of GPCR basal activity is seen. Although it is unlikely that MEDI3185 functions as an inverse agonist in light of its binding site and affinity, we cannot rule out this possibility based on the data presented here. Full functional characterization of MEDI3185 in terms of inhibiting CXCR4/SDF-1 dependent tumor cell signaling, migration, and proliferation will be described elsewhere (manuscript in preparation).
Materials and Methods
Construction and expression of CXCR4 and MEDI3185 variants DNA encoding full length human and mouse CXCR4 (NCBI reference NP_003458.1 and NP_034041.2, respectively) as well as MEDI3185 (MedImmune, human IgG1/k) were generated at MedImmune. CXCR4 and MEDI3185 variants were generated and assembled using PCR by overlap extension. Human and www.tandfonline.commouse CXCR4 and their variants were cloned into the mammalian expression vector pcDNA3.1 (Invitrogen). MEDI3185 wildtype and variants were cloned into an Orip/EBNA-1-based episomal mammalian expression plasmid, pOE. 80 CHO cells were transiently transfected with CXCR4 constructs using Lipofectamine Ò LTX reagent with PLUS TM reagent (Invitrogen) according to the manufacturer's instructions, and harvested for flow cytometry characterization 24 h post-transfection. Constructs encoding MEDI3185 were also transfected into CHO cells using Lipofectamine Ò LTX reagent with PLUS TM reagent, and conditioned media was harvested 5 days post-transfection.
Binding of MEDI3185 to CXCR4 variants About 10 6 CHO cells were transfected with the various CXCR4 constructs, then incubated with either 0.3 mg/ml or a serial dilutions (0.6-0.009 mg/ml) of MEDI3185 in 50 ml phosphate-buffered saline (PBS) containing 1% BSA for 30 min on ice. Cells were washed 3 times with 200 ml ice-cold PBS, and incubated with 1 mg/ml of an anti-human IgG antibody conjugated to FITC (Invitrogen) in 50 ml PBS containing 1% BSA for 30 min on ice. Expression of CXCR4 variants was monitored by incubating the cells with 10 mg/ml APC-conjugated mAb 2B11 (eBioscience) in 50 ml PBS containing 1% BSA for 30 min on ice, and washing 3 times with 200 ml ice-cold PBS. All samples were analyzed using a LSRII flow cytometer (BD Biosciences).
K D values were calculated using a non-linear regression with the GraphPad Prism software.
Competition binding between MEDI3185 and AMD3100
Competition between MEDI3185 and AMD3100 (R&D System) for binding to CXCR4 was assessed by incubating CXCR4-positive Jurkat cells (ATCC) with 1 nM MEDI3185 in the presence of 10 mM AMD3100. This was followed by incubation with 1 mg/ml of an anti-human IgG antibody conjugated to FITC (Invitrogen) in 50 ml PBS containing 1% BSA for 30 min on ice and 3 washes with 200 ml ice-cold PBS. MEDI3185 binding was analyzed using a LSRII flow cytometer (BD Biosciences).
Binding of MEDI3185 variants to CXCR4
Conditioned media from MEDI3185-expressing CHO cells was submitted to IgG quantification using a ForteBIO Octet QK 384. Supernatants were diluted 4-fold with growth media (Invitrogen) and transferred into a 384-well tilted bottom plate (ForteBIO). Purified MEDI3185 was diluted to 100 mg/ml in growth media and a standard curve was generated using serial 2-fold dilutions. Protein A biosensors (ForteBIO) were pre-conditioned with growth media for 10 min and diluted supernatants loaded onto the sensors for~300 sec. Data analysis was carried out using the QK384 Analysis software (ForteBIO). After concentration normalization, MEDI3185 variants were incubated with 293X cells (expressing endogenous CXCR4) at 0.1 and 0.03 mg/ml in 50 ml PBS containing 1% BSA for 30 min on ice. Cells were washed 3 times with 200 ml ice-cold PBS and incubated with 1 mg/ml of an anti-human IgG antibody conjugated to FITC (Invitrogen) in 50 ml PBS containing 1% BSA for 30 min on ice. Cells were then washed 3 times with 200 ml ice-cold PBS. Bound antibodies were detected using a LSRII flow cytometer.
Binding of MEDI3185 to CXCR7 About 10 6 human MCF-7 breast cancer cells (ATCC) were incubated on ice with MEDI3185 at 12.5 or 50 mg/ml in 50 ml PBS containing 1% BSA for 30 min in a 96-well plate. Cells were washed 3 times with 200 ml ice-cold PBS and incubated with 1 mg/ml of an anti-human IgG antibody conjugated to FITC (Invitrogen) in 50 ml PBS containing 1% BSA for 30 min on ice. CXCR7 expression was checked by incubating MCF-7 Figure 9 . MEDI3185 sterically blocks binding of CXCR4 ligands. The mechanism of action of MEDI3185 is proposed based on superimposing the model of the MEDI3185/CXCR4 (LC tint-HC cyan/olive) complex to (a) the structure of human CXCR4 (light blue) bound to viral chemokine vMIP-II (red; PDB ID number 4RWS) 73 or (b) a model of human CXCR4 (gray) bound to SDF-1(magenta). 72 Superimpositions were carried out through the common CXCR4 molecules. Upon binding to CXCR4, MEDI3185 interferes with the access of vMIP-II and SDF-1 ligands through both its light and heavy chains. cells with 12.5 or 50 mg/ml of anti-CXCR7 mAb clone 11G8 (R&D Systems) in 50 ml PBS containing 1% BSA for 30 min on ice, followed by 3 washes with 200 ml ice-cold PBS then incubation with 1 mg/ml of an anti-mouse-IgG mAb conjugated to phycoerythrin (PE; Invitrogen) on ice for 30 min. Cells were then washed 3 times with 200 ml ice-cold PBS. All samples were analyzed using a LSRII flow cytometer.
MEDI3185 structure modeling
The structure of MEDI3185 variable domains was predicted using Discovery Studio 3.5 (DS 3.5; Biovia). Default antibody structure modeling protocols were used to model the frameworks as well as CDRL1, L2, L3, H1 and H2. Briefly, a BLAST search was performed against the protein data bank 81 to identify framework templates (one each for V H , V L and V H /V L interface) exhibiting the highest sequence homology to MEDI3185. 100 models were then constructed through homology modeling using these 3 structural templates. The top scored framework model with the lowest probability density function (PDF) energy was further selected for modeling the CDR loops. CDRs were built by homology modeling using CDR templates sharing the highest sequence identity when compared with MEDI3185 CDRs. In particular, CDR3H was rebuilt by incorporating so-called 'H3 rules' (see below). The top ranked model was then inspected for clashes between atoms, in which case limited minimization was performed for side-chains using CHARMm. The quality of the MEDI3185 model was validated using Profiles 3D and Ramachandran plots of DS 3.5. Illustrations were prepared using PyMOL (Schr€ odinger). Docking ZDOCK in DS 3.5 was used to dock human CXCR4 to the MEDI3185 model. CXCR4 coordinates were prepared for docking using PDB ID number 3ODU 40 and the protein preparation tool in DS3.5. CHARMm force field 63,64 was applied throughout the simulation. Rigid-body docking was performed at a 6 angular step size and clustered for the top 2000 poses. All poses from ZDOCK were processed by filtering for those containing CXCR4 ECL2 within 5 A to MEDI3185. Clusters with the highest density of poses were further considered and went through manual examination to deselect those involving mainly MEDI3185 framework regions in binding. Selected poses were then refined and evaluated using RDOCK and the top ones exhibiting low RDOCK energies were advanced for binding interface analysis. All docking calculations were made with DS 3.5.
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